rethinkPeptides Search
Menu
Home / Research library
Study breakdown

GLP-1 Drugs Improve Quality of Life but Not Mortality in HFpEF Patients

RPEP-148552026Behers, Benjamin J; Sanchez, Christian; Hozayen, Omar; Hozayen, Yousef; Kammer, Rheiner; Corrigan, William T; Stephenson-Moe, Christoph A; Miller, Matthew W; Idriss, Mohab; Cekan, Luis E; King, Alan D; Brown, Garrett H; Hamad, Karen M
evidence
The takeaway

Meta-analysis of 6 RCTs with 5,564 participants finds GLP-1 receptor agonists improve quality of life in HFpEF patients but do not significantly reduce cardiovascular death or worsening heart failure.

5,564 patients across 6 RCTs

Quality of life improved but no significant effect on CV mortality or worsening heart failure

What the researchers found

GLP-1 RAs showed no significant effect on cardiovascular mortality or worsening heart failure events in HFpEF patients but were associated with improved quality of life and favorable safety data across 6 RCTs with 5,564 participants.

Why it matters

HFpEF has very few effective treatments. Even quality-of-life improvements are clinically meaningful for these patients who often have significant symptom burden.

How the study worked

Systematic review and meta-analysis of 6 randomized controlled trials investigating GLP-1 RAs in HFpEF patients, with primary outcomes of cardiovascular mortality and worsening HF events.

What this study cannot tell us

Meta-analysis of heterogeneous trials with different GLP-1 agents and follow-up durations. May be underpowered for mortality outcomes. Quality-of-life measures varied across trials.

How to read the evidence

Systematic review and meta-analysis of RCTs — high-quality evidence synthesis, though heterogeneity across trials noted.

When this study was published

Published in 2026; includes the latest HFpEF-GLP-1 trial data.

The bigger picture

This positions GLP-1 drugs as potential symptom-management tools for HFpEF rather than disease-modifying agents, though longer follow-up may reveal delayed cardiovascular benefits.

Questions still open

  • Would longer treatment with GLP-1 drugs eventually show mortality benefits in HFpEF?
  • Is the quality-of-life improvement driven by weight loss or direct cardiac effects?

Common questions

Do GLP-1 drugs help heart failure?
In HFpEF specifically, GLP-1 drugs improved quality of life but did not significantly reduce cardiovascular deaths or heart failure worsening. They may be most helpful for symptom management.
What is HFpEF?
Heart failure with preserved ejection fraction (HFpEF) means the heart pumps normally but is stiff and doesn't fill properly. It affects 32 million people worldwide and has very few effective treatments.

Read the original research

Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.

Journal of cardiovascular development and disease, 13(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Behers, Benjamin J; Sanchez, Christian; Hozayen, Omar; Hozayen, Yousef; Kammer, Rheiner; Corrigan, William T; Stephenson-Moe, Christoph A; Miller, Matthew W; Idriss, Mohab; Cekan, Luis E; King, Alan D; Brown, Garrett H; Hamad, Karen M. (2026). Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.. Journal of cardiovascular development and disease, 13(2). https://doi.org/10.3390/jcdd13020103